Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications

Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum

(2015) Melissa E. Murray et al.   BRAIN

Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review

(2015) Myria Petrou et al.   MOVEMENT DISORDERS

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

(2015) Craig Curtis et al.   JAMA Neurology

Mild to moderate Alzheimer dementia with insufficient neuropathological changes

(2014) Alberto Serrano-Pozo et al.   ANNALS OF NEUROLOGY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frontotemporal Lobar Degeneration: A Clinical Approach

(2014) Elissaios Karageorgiou et al.   SEMINARS IN NEUROLOGY

C9ORF72 expansion in a family with bipolar disorder

(2013) Miriam H Meisler et al.   BIPOLAR DISORDERS

Neuropathologic Heterogeneity Does Not Impair Florbetapir-Positron Emission Tomography Postmortem Correlates

(2013) Brittany N. Dugger et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Assessing Mild Cognitive Impairment with Amyloid and Dopamine Terminal Molecular Imaging

(2013) R. L. Albin et al.   JOURNAL OF NUCLEAR MEDICINE

Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

(2013) Masahiro Maruyama et al.   NEURON

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography

(2011) J. F. Burke et al.   BRAIN

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

(2011) Christopher M. Clark   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Multimodality imaging characteristics of dementia with Lewy bodies

(2011) Kejal Kantarci et al.   NEUROBIOLOGY OF AGING

Comparing Fludeoxyglucose F18–PET Assessment of Regional Cerebral Glucose Metabolism and [11C]Dihydrotetrabenazine–PET in Evaluation of Early Dementia and Mild Cognitive Impairment

(2010) Roger L. Albin et al.   ARCHIVES OF NEUROLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update

(2009) Ian R. A. Mackenzie et al.   ACTA NEUROPATHOLOGICA

Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia

(2008) Gil D. Rabinovici et al.   ANNALS OF NEUROLOGY